Abstract
Background
Published data regarding the effect of concomitant clopidogrel and proton pump inhibitor (PPI) therapy on cardiovascular outcomes have been conflicting.
Aim
To perform an updated meta-analysis in order to determine changes in risk differences (RD) between primary and secondary outcome analyses.
Methods
Primary analysis was based on definite vascular outcomes, including all cause mortality, cardiac death, myocardial infarction, and/or stroke. Secondary analysis also incorporated probable cardiac events, which included re-hospitalization for cardiac symptoms or revascularization procedures. RD were combined using a random-effects model.
Results
We reviewed 1,204 publications of which 26 studies (16 published articles, 10 abstracts) met inclusion criteria. The meta-analysis of outcomes from the two randomized controlled trials did not show an increased risk (RD 0.0, 95% CI −0.01, 0.01) for adverse outcomes. The meta-analysis of primary outcomes showed a RD of 0.02 (95% CI 0.01, 0.03) for all studies. The meta-analysis for secondary outcomes yielded a RD of 0.02 (95% CI 0.01–0.04) based on 19 published papers and abstracts. When primary and secondary outcomes were combined, the meta-analysis for published papers yielded an overall RD of 0.05 (95% CI 0.03–0.06).
Conclusions
In patients using concomitant clopidogrel and PPI therapy, the risk of adverse cardiac outcomes was 0% based on data from well-controlled randomized trials. Data from retrospective studies and the addition of probable vascular events significantly increased the RD estimates, likely due to lack of adjustment for potential confounders.
Similar content being viewed by others
References
http://www.fda.gov/drugs/drugsafety/publichealthadvisories/ucm190825.htm.
Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009;101:714–719.
Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937–944.
Aubert RE, Epstein RS, Teagarden JR, et al. Proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel medco outcomes study. Circulation. 2008;118:S815.
Dunn SP, Macaulay TE, Brennan DM, et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation. 2008;118:S815.
O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989–997.
Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther. 2010;31:810–823.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.
Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol. 2008;52:1038–1039.
Zairis MN, Patsourakos NG, Makrygiannis SS, et al. The impact of oral proton pump inhibitors on the effectiveness of combined aspirin and clopidogrel drug therapy during the first year after elective coronary stenting. Eur Heart J. 2008;29:134.
Tsiaousis GZ, Zairis MN, Patsourakos NG, et al. Oral proton pump inhibitors and their impact on the effectiveness of dual anti-platelet therapy during the first year after elective coronary stenting. J Am Coll Cardiol. 2009;53:A335.
Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Can Med Assoc J. 2009;180:713–718.
Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909–1917.
Hsu PI, Lai KH. Esomeprazole prevents recurrent peptic ulcers in clopidogrel users with ulcer history. Gastroenterology. 2010;138:S20.
Banerjee S, Weideman RA, Weideman MW, et al. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Am J Cardiol. 2011;107:871–878.
Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363–375.
Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354–362.
Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009;120:2322–2329.
van Boxel OS, van Oijen MG, Hagenaars MP, Smout AJ, Siersema PD. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large dutch cohort study. Am J Gastroenterol. 2010;105:2430–2436.
Kreutz RP, Stanek EJ, Aubert R, et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel medco outcomes study. Pharmacotherapy. 2010;30:787–796.
Wu CY, Chan FK, Wu MS, et al. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel. Gastroenterology. 2010;139:1165–1171.
Sarafoff N, Sibbing D, Sonntag U, et al. Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. Thromb Haemost. 2010;104:626–632.
Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med. 2010;170:704–710.
Tentzeris I, Jarai R, Farhan S, Brozovic I, Smetana P, Geppert A, et al. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. Thromb Haemost. 2010;104:1211–1218.
Torguson R, Chou C, Kaneshige K, et al. Does proton pump inhibitor use following percutaneous coronary intervention with drug-eluting stents impact clinical outcome? Circulation. 2009;120:S968.
Zairis MN, Tsiaousis GZ, Patsourakos NG, Georgilas AT, Kontos CF, Adamopoulou EN, et al. The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. Can J Cardiol. 2010;26:54–57.
Gupta E, Bansal D, Sotos J, Olden K. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci. 2010;55:1964–1968.
Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010;153:378–386.
Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med. 2010;152:337–345.
Evanchan J, Donnally MR, Binkley P, Mazzaferri E. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol. 2010;33:168–171.
Harjai K, Orshaw P, Boura J, Rogers G. Six-month outcomes with or without proton-pump inhibitors after successful PCI: insights from the Guthrie PCI registry. J Am Coll Cardiol. 2010;55:A179.
Ching G, Li DD, McKay R, Mather J, Lundbye J. Proton pump inhibitors increase major adverse cardiac events among post percutaneous coronary intervention patients on clopidogrel. Circulation. 2009;120:S936–S937.
Ramirez JF, Selzer F, Chakaprani R, et al. Proton pump inhibitor and clopidogrel combination is not associated with adverse clinical outcomes after PCI: the NHLBI dynamic registry. J Am Coll Cardiol. 2009;53:A27.
Banerjee S, Varghese C, Weideman RA, Weideman MW, Little BB. Proton pump inhibitors increase the risk of major adverse cardiovascular events in post-PCI patients who are on clopidogrel. Eur Heart J. 2009;30:P653.
Kim MS, Jung SY, Kim YJ, Choi NK, Park BJ. Association of proton pump inhibitors with clopidogrel effectiveness in elderly stroke patients. Pharmacoepidemiol Drug Saf. 2009;18:S7–S8.
Sweeny JM, Kini A, Muntner P, Jakkula M, Farkouh M, Sharma S. Mortality associated with proton pump inhibitors following percutaneous coronary interventions with drug eluting stents. Circulation. 2009;120:S936.
Wang SS-W, Tsai S–S, Hsu P-C, Yang C-Y, Wu D-C. Concomitant use of clopidogrel and proton pump inhibitors or cimetidine after acute myocardial infarction would increase the risk of re-infarction. Am J Gastroenterol. 2009;104:3116–3117.
Conflict of interest
Lauren B. Gerson MD, MSc: Consultant, Takeda, Eisai, Xenoport; grant support: Santarus, Inc. Donal McMahon, Ingram Olkin, Christopher Stave, and Stanley G. Rockson have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Appendix—Search Strategy
Appendix—Search Strategy
PUBMED
Search Dates: 1947—October 27, 2010
MyNCBI: clopidrogel/clopidrogel
-
1.
(“anti-ulcer agents” OR “Proton Pump Inhibitors” OR “proton pump”[tw] OR ppi[tw] OR omeprazole[tw] OR prilosec[tw] OR esomeprazole[tw] OR nexium[tw] OR lansoprazole[tw] OR prevacid[tw] OR pantoprazole[tw] OR protonix[tw] OR rabeprazole[tw] OR aciphex[tw] OR dexlansoprazole[tw] OR kapidex[tw])
-
2.
(clopidogrel[tw] OR Iscover[tw] OR plavix[tw] OR “PCR 4099”[tw] OR “SR 25989”[tw])
-
3.
1 AND 2 = 237
SCOPUS
Search Dates: 2009–October 27, 2010
-
1.
(((TITLE((clopidogrel OR iscover OR plavix OR “PCR 4099” OR “SR 25989” OR “SR 25990” OR “SC 25989C”)) AND TITLE((“Proton Pump” OR omeprazole OR prilosec OR esomeprazole OR nexium OR lansoprazole OR prevacid OR pantoprazole OR protonix OR rabeprazole OR aciphex OR dexlansoprazole OR kapidex))))
-
2.
((ABS((clopidogrel OR iscover OR plavix OR “PCR 4099” OR “SR 25989” OR “SR 25990” OR “SC 25989C”)) AND ABS((“Proton Pump” OR omeprazole OR prilosec OR esomeprazole OR nexium OR lansoprazole OR prevacid OR pantoprazole OR protonix OR rabeprazole OR aciphex OR dexlansoprazole OR kapidex))))) AND (LIMIT-TO(PUBYEAR, 2010) OR LIMIT-TO(PUBYEAR, 2009))
-
3.
1 OR 2 = 176 citations
BIOSIS
1926–October 27, 2010
-
1.
(“Proton Pump” OR omeprazole or prilosec or esomeprazole or nexium or lansoprazole or prevacid or pantoprazole or protonix or rabeprazole or aciphex or dexlansoprazole or kapidex)
-
2.
(clopidogrel or Iscover or plavix or “PCR 4099” or “SR 25989” or “SR 25990” or “SC 25989C”)
-
3.
1 AND 2 = 257
EMBASE
1974–2009
-
1.
Anti-ulcer agents! OR proton pump inhibitors! OR proton pump inhibitor! OR proton pumps!(L)AI OR omeprazole OR prilosec OR esomeprazole OR nexium OR lansoprazole OR prevacid OR pantoprazole OR protonix OR rabeprazole OR aiphex OR dexlansoprazole OR kapidex
-
2.
Clopidogrel OR iscover OR plavix OR PCR(W)4099 OR SR(W)25989 OR SR(W)25990 OR SC(W)25989C OR ticlopidine
-
3.
Heart infarction! OR heart death! OR drug safety! OR cardiovascular risk! OR acute coronary syndrome! OR kidney failure! OR comorbidity! OR gastrointestinal hemorrhage! OR bleeding! OR stent thrombosis! OR myocardial()infarction OR heart()attack OR cardiac()arrest OR cardiac()-death OR death OR survival OR stroke! OR graft occlusion! OR adverse OR stent?(2 N)occlu? OR angina OR ‘Complication’ OR ‘Adverse Drug Reaction’ OR ‘Drug Toxicity’
-
4.
1 AND 2 AND 3 = 678
Rights and permissions
About this article
Cite this article
Gerson, L.B., McMahon, D., Olkin, I. et al. Lack of Significant Interactions Between Clopidogrel and Proton Pump Inhibitor Therapy: Meta-Analysis of Existing Literature. Dig Dis Sci 57, 1304–1313 (2012). https://doi.org/10.1007/s10620-011-2007-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-011-2007-1